Extensive clinical use has established beyond doubt the value of sulfapyridine and sulfathiazole in the treatment of pneumococcic pneumonia. Among the many similar compounds that have been synthesized, one in particular has shown sufficient promise in preliminary studies to be worthy of clinical trial. This compound, sulfadiazine (2-sulfanilamidopyrimidine) is the pyrimidine analogue of sulfapyridine, synthesized by Roblin and his associates.1 Feinstone and his co-workers2 administered sulfadiazine to various laboratory animals and obtained higher average blood levels than after the administration of similar dosages of sulfapyridine or sulfathiazole. The therapeutic effects with sulfadiazine were equal or superior to those with sulfapyridine or sulfathiazole, and the toxic reactions were less frequent. Studies on the absorption and excretion of sulfadiazine in human beings have been made by several groups of investigators3 who agreed that higher levels of the drug in the blood were obtained and that these persisted over a
DOWLING HF, HARTMAN CR, SUGAR SJ, FELDMAN HA. THE TREATMENT OF PNEUMOCOCCIC PNEUMONIA WITH SULFADIAZINE. JAMA. 1941;117(10):824–826. doi:10.1001/jama.1941.02820360006003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: